



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/648,310	08/25/2000	Paul B. Fisher	62943/JPW/JML	6406

7590

12/14/2004

Lisa B. Kole
Baker Botts L.L.P.
30 Rockefeller Plaza
New York, NY 10112

EXAMINER

YU, MISOOK

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 12/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/648,310

Applicant(s)

FISHER ET AL.

Examiner

MISOOK YU, Ph.D.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 September 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 54-85 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 54-57 and 70-73 is/are allowed.
- 6) ☒ Claim(s) 58-69 and 74-85 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 09/20/2004.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: _____.

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/02/2004, and 09/20/2004 has been entered.

Claims 54-85 are pending and examined on merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

This Office action contains new grounds of rejection.

Claim Rejections - 35 USC § 112, Withdrawn

The rejection of claims under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is withdrawn in view of the amendment.

The rejection of claims 54-85 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making an art-known enhance element, does not reasonably provide enablement for an native enhancer element controlling the transcription of SEQ ID NO:2 or 4 coding region is also withdrawn in view of the amendment.

The Following are New Grounds of Rejections

Claim Rejections - 35 USC § 112

Claims 58-69, and 74-85 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated host cell for protein expression purposes, does not reasonably provide enablement for host cell in gene therapy or any other in vivo use. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

This enablement rejection is made because claims 58-69, and 74-85 recite several host cells, for example, thyroid cancer cells, and central nervous system tumor cells not commonly used in the art for in vitro protein expression. Further, the specification at the abstract, and page 23 contemplates a gene therapy using the newly discovered nucleic acids encoding a human and a rat Progression Suppressed Gene-13, therefore the invention claimed in claims 58-69, and 74-85 are interpreted as drawn to gene therapy.

Art Unit: 1642

The specification does not teach method of a gene therapy. The art recognizes that gene therapy is not a trivial matter. The specification does not teach any method of overcoming technical difficulties the art has been facing with the gene therapy. For example, Friedmann (Scientific American, June 1997, pages 96-101), Verma and Somia (1997, *Nature*, vol. 389, pages 239-242), and Rubanyi (2001, *Molecular Aspects of Medicine* 22, pages 113-142) all teach that gene therapy art still faces major hurdle to overcome. Verma et al. (*Nature* 1997, **389**: 239-242) teach that the Achilles heel of gene therapy is gene delivery. Verma et al. state that the ongoing problem is the inability to deliver genes efficiently and to obtain sustained expression. Rubanyi at the abstract teaches that the prerequisite of successful gene therapy includes "therapeutically suitable genes with a proven role in pathophysiology of the disease". The specification for example at Figs. 6, and 8 discloses the PSGen 13 suppresses anchorage independent growth in cell line cells, but does not teach which disease could be treated to use the gene. Thus, the instant specification fails at the first prerequisite of a gene therapy because the specification does not teach involvement of the disclosed nucleic acid sequences with a proven role in pathophysiology of a disease. Friedman summarizes the current state of gene therapy as "treating disease by providing needed gene remains a compelling idea, but clinical and basic researchers still have much to do before gene therapy can live up to its promise" (note the italicized headline at the top of page 96). The instant specification does not teach a single technical problem being solved for gene therapy art.

Art Unit: 1642

In view of the preponderance of evidence establishing the state of the art, now and at the time the application was filed, and the level of unpredictability associated therewith, in the absence of a disclosure using a human or a rat Suppressed Gene-13 gene transcript encoding SEQ ID NO:2 or 4 for gene therapy, and exemplification that is reasonably commensurate in scope with the claims, it appears that skilled artisan could not make and use the claimed invention with a reasonable expectation of success without having the need to perform an undue amount of experimentation.

Amending claims 58, 61, 64, 67, 73, 77, and 80 to recite "isolated" before "host cell" can obviate these grounds of rejection.

Allowable Subject Matter

Claims 54-57, and 70-73 allowed.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey C Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read 'Misook Yu', with a stylized flourish at the end.

MISOOK YU, Ph.D.
Examiner
Art Unit 1642